We believe that BioGlue in Japan, Cardiogenesis, and PerClot represent attractive top line growth and margin expansion opportunities for the company this year and in 2013 and beyond.
Cardiac tissue revenues for the first quarter of 2012 increased 8% compared to the corresponding period in 2011. As compared to the prior year, unit shipments of cardiac tissues went up 1% for the quarter. Vascular tissue revenues decreased 6% compared to the prior year's quarter on a 3% decrease in units for the quarter.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts